Pidontas develops affordable genetic therapies for neurodegenerative diseases by leveraging cutting‑edge transposable element technology to locate diseased cells in vivo and deliver regenerative genetic material directly to them. The platform enables precise, cell‑specific gene integration, aiming to restore function in affected neural tissue. By focusing on scalable, accessible treatments, Pidontas seeks to make advanced gene‑based regeneration available to patients worldwide.
Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative diseases currently lack therapies that can directly repair damaged neurons, leading to progressive loss of function and limited treatment options for patients worldwide.
Solution
Pidontas leverages transposable element technology to identify diseased cells within the nervous system and deliver therapeutic genetic material directly to those cells in vivo. By enabling precise, targeted gene integration, the platform promotes cellular regeneration and functional recovery without the need for invasive procedures. The approach is designed for scalable manufacturing, aiming to keep advanced genetic treatments affordable and accessible. Pidontas’ solution addresses the underlying cause of neurodegeneration rather than merely managing symptoms, offering a pathway to disease-modifying therapy.
Target Audience
Primary customers are pharmaceutical and biotech companies developing treatments for neurodegenerative disorders, as well as research institutions seeking a platform for targeted gene therapy in the nervous system.
Features
- In vivo cell targeting using engineered transposable elements that home to diseased neurons
- Site‑specific gene integration that inserts regenerative DNA sequences without disrupting native genome function
- Modular therapeutic payloads allowing customization for different neurodegenerative indications
- Scalable, GMP‑compatible production process to reduce manufacturing costs
- Built‑in safety mechanisms, including self‑limiting transposition and off‑target monitoring